Holen Sie sich die Stockscreener-App
2.15
2.71%
-0.06
Vorhandelsmarkt:
2.20
0.05
+2.33%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ESPR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$2.21
Offen:
$2.23
24-Stunden-Volumen:
4.94M
Relative Volume:
0.86
Marktkapitalisierung:
$407.34M
Einnahmen:
$116.33M
Nettoeinkommen (Verlust:
$-209.25M
KGV:
-1.0142
EPS:
-2.12
Netto-Cashflow:
$-135.49M
1W Leistung:
-4.02%
1M Leistung:
-1.83%
6M Leistung:
-10.04%
1J Leistung:
+6.44%
1-Tages-Spanne:
$2.14
$2.25
1-Wochen-Bereich:
$2.05
$2.34
52-Wochen-Spanne:
$1.58
$3.94
Esperion Therapeutics Inc Stock (ESPR) Company Profile
Firmenname
Esperion Therapeutics Inc
Sektor
Telefon
734-887-3903
Adresse
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Vergleichen Sie ESPR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
2.15 | 407.34M | 116.33M | -209.25M | -135.49M | -2.12 |
|
ZTS
Zoetis Inc
|
167.53 | 75.58B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.24 | 41.78B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.10 | 41.53B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.82 | 24.72B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
145.88 | 14.77B | 2.24B | 385.90M | 440.10M | 3.73 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-18 | Eingeleitet | Goldman | Neutral |
| 2024-12-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-06-20 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-08-01 | Hochstufung | Northland Capital | Under Perform → Market Perform |
| 2023-06-15 | Hochstufung | BofA Securities | Underperform → Buy |
| 2023-03-16 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-03-16 | Herabstufung | Northland Capital | Market Perform → Under Perform |
| 2023-03-07 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2023-02-27 | Fortgesetzt | BofA Securities | Neutral |
| 2023-02-24 | Hochstufung | Jefferies | Hold → Buy |
| 2023-02-03 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-08-03 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2022-05-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-03-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-19 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2021-10-14 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-05-05 | Herabstufung | Stifel | Buy → Hold |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-11 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-02-12 | Herabstufung | Jefferies | Buy → Hold |
| 2021-02-09 | Herabstufung | Goldman | Neutral → Sell |
| 2021-01-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-11-10 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-09-29 | Fortgesetzt | JP Morgan | Underweight |
| 2020-08-11 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2020-04-01 | Fortgesetzt | BofA/Merrill | Buy |
| 2020-03-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-24 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2020-02-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-09-16 | Hochstufung | Goldman | Sell → Neutral |
| 2019-05-29 | Herabstufung | Goldman | Neutral → Sell |
| 2019-05-06 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-04-26 | Hochstufung | Goldman | Sell → Neutral |
| 2019-03-13 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-01-07 | Bestätigt | Needham | Strong Buy |
| 2018-12-13 | Eingeleitet | Goldman | Sell |
| 2018-10-29 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2018-10-16 | Eingeleitet | BTIG Research | Buy |
| 2018-08-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-07-11 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2018-05-03 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-05-02 | Herabstufung | BofA/Merrill | Buy → Underperform |
Alle ansehen
Esperion Therapeutics Inc Aktie (ESPR) Neueste Nachrichten
Esperion Therapeutics chief commercial officer sells $277 in stock By Investing.com - Investing.com Australia
Esperion Therapeutics CFO sells shares worth $20 By Investing.com - Investing.com South Africa
Esperion Therapeutics chief commercial officer sells $277 in stock - Investing.com India
Esperion Therapeutics CFO sells shares worth $20 - Investing.com India
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Short Interest Update - MarketBeat
Barclays PLC Grows Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat
Esperion stock falls on higher operating expense forecast - MSN
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Esperion Therapeutics' (ESPR) Buy Rating Reiterated at HC Wainwright - MarketBeat
IMTX: 3 Small-Cap Healthcare Stocks With Big Upside Potential - StockNews.com
Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET. - The Manila Times
Esperion to Host KOL Event on NEXLETOL, NEXLIZET Real-World Impact in Cholesterol Management - StockTitan
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q2 2024 Earnings Call Transcript - MSN
Best 5 Penny Stocks With Great Financial Health (January 2025) - Investing.com
Esperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference - The Bakersfield Californian
Esperion to Present at J.P. Morgan Healthcare Conference: Showcasing Non-Statin Breakthroughs - StockTitan
FINAL DEADLINE ALERT: Kaskela Law LLC Announces Shareholder Class Action Lawsuit Against Esperion Therapeutics, Inc. and Encourages Investors with Losses in Excess of $250,000 to Immediately Contact the Firm - AccessWire
Short Interest in Esperion Therapeutics, Inc. (NASDAQ:ESPR) Decreases By 16.5% - MarketBeat
ZTS: 3 Healthcare Innovators with Analyst-Endorsed Upside - StockNews.com
Public Employees Retirement System of Ohio Buys New Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat
ESPREsperion Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Wellington Management Group LLP Grows Stock Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat
Cantor Fitzgerald Estimates ESPR FY2024 Earnings - MarketBeat
FOLD: 3 High-Growth Biotech Stocks to Watch - StockNews.com
Esperion Therapeutics CFO Benjamin Halladay sells $7,865 in stock By Investing.com - Investing.com Canada
Esperion Therapeutics CFO Benjamin Halladay sells $7,865 in stock - Investing.com India
Cantor Fitzgerald Initiates Coverage of Esperion Therapeutics (ESPR) with Overweight Recommendation - MSN
Esperion Therapeutics issues $100M in new convertible notes - Investing.com
Esperion Therapeutics issues $100M in new convertible notes By Investing.com - Investing.com UK
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Esperion Therapeutics (NASDAQ:ESPR) Coverage Initiated by Analysts at The Goldman Sachs Group - MarketBeat
Esperion secures $150 million loan and $100 million notes By Investing.com - Investing.com UK
Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions - GlobeNewswire
Esperion Secures $250M in Strategic Financing, Restructures 80% of Debt in Major Deal - StockTitan
esperion stock faces uphill battle on bempedoic acid growth says Goldman - Investing.com Canada
Cantor Fitzgerald starts coverage on Esperion stock, highlights strong potential for NEXLETOL - Investing.com Canada
Cantor Fitzgerald Initiates Coverage on Esperion Therapeutics (NASDAQ:ESPR) - MarketBeat
Esperion announces $210M convertible debt financing - MSN
Esperion Therapeutics, Inc. announced that it expects to receive $42.5 million in funding - Marketscreener.com
Future of Heterozygous Familial Hypercholesterolemia Drug - openPR
Esperion Therapeutics' (ESPR) Buy Rating Reaffirmed at Needham & Company LLC - MarketBeat
Esperion Announces $210 Million Convertible Debt Financing - GlobeNewswire
Esperion Secures $210M Debt Restructuring Deal with Strategic Convertible Notes Offering - StockTitan
Esperion secures licensing deal for heart drugs in Israel By Investing.com - Investing.com Canada
Esperion Partners with Neopharm to Commercialize NEXLETOL® - GlobeNewswire
Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET - The Bakersfield Californian
Esperion Therapeutics Expands Global Reach with New Israeli Licensing Deal for Cholesterol Drugs - StockTitan
Finanzdaten der Esperion Therapeutics Inc-Aktie (ESPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):